TrioxBio Inc., a Delaware Corporation, is a clinical-stage biotech company specializing in the development of compounds to treat diseases and medical conditions related to the pathological overproduction of Nitric Oxide (NO).

Over 100 white papers and articles have been published documenting how the overproduction of nitric oxide is linked to harmful effects on the human body and strongly believed to be responsible for numerous medical conditions, such as migraine, cluster headache, intradialytic hypotension and vasoplegic syndrome, two examples of severe hypotension.

TrioxBio's API, S-ethylisothiouronium diethylphosphate, MTR-104, is a Nitric Oxide Synthase (NOS) inhibitor which blocks the production of nitric oxide, preventing the dilation of blood vessels and the other detrimental effects caused by excessive NOS activity.

TrioxBio's leading candidate MTR-107, indicated for the prevention of recurrent intradialytic hypotension an unmet medical need, was designated with ODD in August 2016, furthermore Fast Track designation was submitted in May 2018. MTR-107 phase IIb clinical studies activities planned for Q4 of 2018.

Our mission is our commitment to improving quality of life. By way of our existing products and pending approvals across our various markets, our aim is to provide patients with better access to high-quality, cost-effective medicines in key therapeutic areas.

News & Media

May 02, 2018:

Dr. Dov Tamarkin was assigned as the chairmen of the board. Dr. Dov Tamarkin-founder and former CEO of Foamix Israel, led the company through the required regulatory process in multiple countries (including FDA), and extensive experience in IP, clinical study design, drug manufacturing and leading biotech platforms.

March 17, 2018:

" TrioxBio Inc. submitted  a fast tract registration request to FDA authorities for the treatment of  recurrent symptomatic intradialytic hypotension (IDH)."

 August 29, 2016:

"The FDA's Office of Orphan Products Development granted TrioxBio Inc. its orphan-drug designation request of S-ethylisothiouronium diethylphosphate (MTR-107) for treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH) including symptomatic hypotension in the immediate post-dialytic period."

January 17, 2016:

" TrioxBio Inc. submitted  an Orphan-drug designation request to FDA authorities for the treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH)."